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Dear Editor,
Therapy-related myeloid neoplasms (t-MNs) are a unique
clinical entity occurring as late complication of chemotherapy
and radiotherapy administered for a primary disease [1]. Ac-
cording to the WHO classification, t-MNs are thought to be
due to mutational events in hematopoietic stem and precursor
cells (HSPCs) induced by these treatments [2]. However, no
consistent biomarker has been identified yet that classifies a
particular neoplasm as “therapy-related” [3]. This raises the
possibility that other mechanisms may also be operational in
their pathogenesis. We and others [4], therefore, hypothesized
that mutations contributing to leukemic transformation were
preexisting in HSPCs of some of these individuals.
In this study, we selected patients with therapy-related
AML (t-AML) following cytotoxic treatment of malignant
lymphomas as bone marrow (BM) biopsies are routinely
performed during their initial staging procedures. We focused
on the TP53 gene which is frequently mutated in t-AMLs
exhibiting a potentially important role in leukemogenesis
[5–7]. We identified a somatic heterozygous 64-base pair
duplication (Fig. 1a) in a 71 year-old male Caucasian patient
who suffered from Hodgkin lymphoma 13 years ago treated
by chemotherapy and radiotherapy. To search for potential
cooperating mutations, we performed Ion Torrent deep se-
quencing of recurrently mutated genes in AML [8]. However,
no further mutations could be identified (see Supplementary
Information for list of genes).
We established a highly sensitive PCR assay specific for
this rearrangement (Fig. 1b) and could unambiguously dem-
onstrate the presence of the TP53mutation in the patient’s BM
obtained at the time of the lymphoma staging (Fig. 1c). Sur-
prisingly, the TP53 duplication was also detected in a reactive
lymphadenitis sample obtained 7 years before lymphoma
diagnosis (Fig. 1c). To further demonstrate that expansion of
the TP53 mutated clone occurred following cytotoxic treat-
ment, we quantified the TP53 duplication by digital PCR
(dPCR) which showed that the relative proportion of mutated
cells increased substantially in the t-AML specimen (Fig. 1d).
It, furthermore, confirmed the TP53 duplication being a so-
matically acquired event as it was absent from a skin biopsy
obtained at the time of the leukemia diagnosis.
In the case report presented here, we were able to demon-
strate that cytotoxic treatment did not induce a leukemia-
specific mutation but rather may have facilitated the expan-
sion of a pre-leukemic clone harboring a somatic TP53 muta-
tion. Since dPCR data quantifying the TP53 duplication were
comparable in lymph node and pretreatment BM, the mutation
might have occurred in HSPCs that retained their lymphoid as
well as myeloid differentiation potential and remained dor-
mant for many years. This finding challenges current concepts
of therapy-related leukemogenesis and is in line with data
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of Hematology [4]. There, somatic TP53 variants could be
identified at low frequencies in mobilized peripheral blood
leukocytes of two t-MDS/t-AML cases years before diagno-
sis. However, in clinical practice, HSPC harvests from periph-
eral blood are performed following intense chemotherapy
including application of recombinant granulocyte-colony fac-
tor. Here, we provided definitive evidence that a leukemia-
specific mutation could be found in HSPCs before any cyto-
toxic treatment was administered.
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Fig. 1 Detection of a preexisting TP53 mutation in a patient with
therapy-related acute myeloid leukemia (t-AML). a Bi-directional
Sanger sequencing demonstrates the leukemia-specific 64 bp
duplication in exon 4 of the TP53 gene. b The primer pair enables the
detection of the duplication to a dilution of 0.01 % t-AML DNA in
normal control DNA. Analysis of four AML control samples revealed
the absence of this duplication in all of them (data not shown). c The 62-
base pair product (upper band) specific for the TP53 duplication could be
detected in the bone marrow (BM) obtained at diagnosis of Hodgkin
lymphoma as well as in a lymphadenitis specimen (LN) the latter
obtained 20 years before diagnosis of t-AML. The lower band refers to
primer dimers, GAPDH (lower gel) served as control gene for DNA
integrity. d Expansion of cells with the TP53 duplication determined by
digital PCR. Relative ratios between mutant TP53 fragments and BRAF
wild-type fragments were assessed using the QuantStudio 3D Digital
PCR System (Life Technologies, Carlsbad, CA). Copy number changes
at theBRAF locus of the t-AMLwere excluded using low coveragewhole
genome sequencing to ensure that BRAF is suitable as a reference and not
subjected to copy number changes. Data shown are means of assays
performed in duplicates and error bars indicate 95 % confidence
intervals. BM bone marrow; LN lymphadenitis sample; NTC no
template control; WGAwhole genome amplified DNA
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